ARS PHARMACEUTICALS INC (SPRY)
US82835W1080 - Common Stock
ChartMill assigns a Buy % Consensus number of 89% to SPRY. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 19.38. This target is 115.57% above the current price.
SPRY was analyzed by 9 analysts. The buy percentage consensus is at 89. So analysts seem to be very confident about SPRY.
In the previous month the buy percentage consensus was at a similar level.
SPRY was analyzed by 9 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-03-11 | Wedbush | Reiterate | Outperform -> Outperform |
| 2024-03-05 | Leerink Partners | Upgrade | Market Perform -> Outperform |
| 2023-11-13 | Wedbush | Maintains | Outperform -> Outperform |
| 2023-09-21 | Wedbush | Maintains | Outperform -> Outperform |
| 2023-09-20 | William Blair | Downgrade | Outperform -> Market Perform |
| 2023-08-14 | Wedbush | Reiterate | Outperform -> Outperform |
| 2023-06-21 | Wedbush | Maintains | Outperform -> Outperform |
| 2023-05-18 | Wedbush | Reiterate | Outperform -> Outperform |
| 2023-05-12 | Wedbush | Reiterate | Outperform -> Outperform |
| 2023-05-10 | Wedbush | Reiterate | Outperform |
| 2023-01-31 | Wedbush | Initiate | Outperform |
| 2023-01-04 | William Blair | Initiate | Outperform |
| 2022-12-13 | SVB Leerink | Initiate | Outperform |